Skip to main content
. 2023 Sep 20;14:1202325. doi: 10.3389/fphar.2023.1202325

TABLE 3.

Incidence of the most common adverse events in both groups.

Tacrolimus group (n = 100) Hydrocortisone group (n = 100)
Skin burning sensation, No. (%) 60 (60%)* 12 (12%)
Skin erythema, No. (%) 20 (20%)* 4 (4%)
Skin atrophy, No. (%) 0 (0%) 8 (8%)*
Skin infection, No. (%) 4 (4%) 6 (6%)

*(p ≤ 0.05) is considered significant.